Johnson Yiu-Nam Lau

This inventor holds 30 USPTO granted patents and 24 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Immunotherapy Development. Top assignees: Versitech, Inc., Athenex Hk Innovative Limited, Nansha Biologics (Hong Kong) Limited. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Johnson Yiu-Nam Lau. Retrieved from https://idiyas.com/inventor/johnson-yiu-nam-lau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 24)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 13)

EPO Patents = 4 (Patent Applications = 24)

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 18(Granted Patents)

Location History:

Houston, CA (2023)
Houston, TX (US) (2019 - 2024)
Newport Beach, CA (US) (2020 - 2024)

Company Filing History:

Athenex Hk Innovative Limited

patents

3 out of 3

Nansha Biologics (Hong Kong) Limited

Avalon Photonics (Hk) Limited

patents

7. 2 out of 2

Health Hope Pharma Ltd

Avalon Polymills (Hk) Limited

patent

10. 1 out of 1

Avalon Polytom (Hk) Limited

patent

11. 1 out of 1

Avalon Spinecare (Hk) Limited

patent

12. 1 out of 1

Emv Enhance (Hk) Limited

patent

13. 1 out of 1

Nansha Biologies (Hk) Limited

patent

14. 1 out of 1

Nansha Biologies (Hong Kong) Limited

patent

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Actinic Keratosis

Antimicrobial Treatment

Amino Acid Depletion

Vaccine Production

Immunogenicity

IL-11 Composition

Cancer Treatment

Phototherapy Device

Viral Infections

Therapeutic Combinations

Scoliosis Evaluation

Pegylation

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667576 - Methods of treating and/or preventing actinic keratosis (2026-06-30),

2. 12252841 - Durable antimicrobial treatment of textile for use in healthcare environment (2025-03-18),

3. 12227494 - Polymorphisms of HM30181 mesylate (2025-02-18),

4. 12213955 - Compositions and methods for broad-spectrum antiviral therapy (2025-02-04),

5. 12144856 - Compositions and methods for enhancing immune response to vaccination and improving vaccine production (2024-11-19),

6. 12090029 - Devices and methods for enhancing immunogenicity to intradermal vaccination (2024-09-17),

7. 11963942 - Oral taxane compositions and methods (2024-04-23),

8. 11931417 - Methods of preparing a pegylated human IL-11 composition (2024-03-19),

9. 11898180 - Compositions and methods for amino acid depletion therapy (2024-02-13),

10. 11826425 - Compositions and methods for treatment of enterovirus infection (2023-11-28),

11. 11752156 - Compositions and methods for treating hyperproliferative skin disorders (2023-09-12),

12. 11752139 - Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer (2023-09-12),

13. 11739089 - Acetamido-phenyltetrazole derivatives and methods of using the same (2023-08-29),

14. 11739079 - Polymorphisms of HM30181 mesylate (2023-08-29),

15. 11629367 - Systems and methods for production of recombinant IL-11 in yeast (2023-04-18),

Title: **Innovative Contributions of Johnson Yiu-Nam Lau: A Patent Portfolio of 28 Inventions**

Introduction

Johnson Yiu-Nam Lau, based in Houston, Texas, is a notable inventor with an impressive portfolio of 28 patents. His work primarily focuses on advancements in pharmaceuticals, particularly in areas that enhance the efficacy of cancer treatment and antiviral therapies. Lau's innovative contributions have the potential to significantly improve patient outcomes.

Latest Patents

Among Johnson Lau's latest patents is a significant innovation involving polymorphisms of HM30181 mesylate. This invention aims to improve the absorption of cancer chemotherapy drugs, such as paclitaxel. The patent details various polymorphisms of HM30181, including B, D, E, F, G, H, I, J, K, L, and M, alongside their physical properties and methods for preparation and characterization.

Another noteworthy patent describes compositions and methods for broad-spectrum antiviral therapy. It utilizes AM580 and structurally related compounds, which have shown effectiveness in treating infections by a wide array of RNA and DNA viruses while also minimizing associated inflammation. The activity of these compounds operates independently of RAR-α signaling and does not stimulate the host's innate immune response, highlighting their unique mechanism through modulation of lipogenesis.

Career Highlights

Throughout his career, Johnson Lau has made significant strides in the pharmaceutical industry. He has worked with therapeutic companies, including Versitech, Inc. and Athenex HK Innovative Limited, where his innovative approaches and technical expertise have driven numerous projects forward in drug development and patenting.

Collaborations

Johnson Lau has collaborated with industry professionals, including Min-Fun Rudolf Kwan and Kwok Yung Yuen. These collaborations illustrate the importance of teamwork in advancing scientific research and the development of cutting-edge therapies.

Conclusion

Johnson Yiu-Nam Lau's contributions to the field of pharmaceuticals through his innovative patents underline the impact of research and development in improving healthcare. With a focus on enhancing cancer treatment and antiviral therapies, his inventions not only reflect ingenuity but also a commitment to addressing critical healthcare challenges. His work will undoubtedly continue to influence future innovations and clinical practices.

Profile summary based on public USPTO records.